CRYSTALLINE ANTIBODY FORMULATIONS

To provide anti-PCSK9 antibody crystals, and methods of making such antibody crystals and formulations comprising the antibody crystals.SOLUTION: The invention relates to: crystals of anti-PCSK9 immunoglobulin type G (IgG) antibodies (more specifically, antibody 21B12) that are suitable for use in c...

Full description

Saved in:
Bibliographic Details
Main Authors TIMOTHY DAVID OSSLUND, TWINKLE R CHRISTIAN, CHRISTI L CLOGSTON
Format Patent
LanguageEnglish
Japanese
Published 15.10.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:To provide anti-PCSK9 antibody crystals, and methods of making such antibody crystals and formulations comprising the antibody crystals.SOLUTION: The invention relates to: crystals of anti-PCSK9 immunoglobulin type G (IgG) antibodies (more specifically, antibody 21B12) that are suitable for use in crystalline formulations for parenteral administration; solutions, salts and methods for producing such crystals; methods of using such crystals to prepare crystalline formulations for use as medicaments; and methods of using such crystalline formulations to treat mammals, particularly humans.SELECTED DRAWING: Figure 1A 【課題】抗ＰＣＳＫ９抗体結晶、このような抗体結晶及び抗体結晶を含む製剤を作製する方法を提供すること。【解決手段】本発明は、非経口投与用の結晶製剤での使用に好適な抗ＰＣＳＫ９免疫グロブリンＧ型（ＩｇＧ）抗体（より具体的には、抗体２１Ｂ１２）の結晶；このような結晶を製造するための溶液、塩及び方法；医薬として使用するための結晶製剤を調製するために、このような結晶を使用する方法、ならびに哺乳動物、特にヒトを処置するために、このような結晶製剤を使用する方法に関する。【選択図】図１Ａ
Bibliography:Application Number: JP20200114780